Fig 1. The effect of pravastatin on the release of angiogenic factors from the human placenta.

Maternal concentrations of placental growth factor (PlGF; A), soluble fms-like tyrosine kinase 1 (sFlt-1; B) and soluble endoglin (sEng; C) and Fetal concentrations of sFlt-1 (D) were determined in samples collected from the maternal and fetal reservoirs of cotyledons perfused in the absence (Cntl) or presence of 0.2 micromol/L pravastatin in the maternal circulation only (PraM) as described in the "materials and methods" section. The concentrations of the different factors were normalized to gram (g) of perfused cotyledon. Cntl: n = 8; PraM: n = 11. E. The concentrations of sFlt-1 were determined in medium samples collected from placental explants incubated in the absence or presence of 0.2 micromol/L pravastatin for 5 h (n = 5). F-G. The concentrations of sFlt-1 (F) and sEng (G) were determined in samples collected from placental explants incubated in the absence or presence of pravastatin (Pra; 1, 10, 200 or 2000 micromol/L) for 72 h (n = 5). E-G. The concentrations were normalized to milligram of cultured tissue and expressed relative to Cntl (untreated cultures).